Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Terminated × rasburicase × Clear all

Phase

Phase 2 2 Phase 3 1

Status

Completed 2 Terminated 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Hyperuricemia 1

Interventions

Cisplatin 62 Carboplatin 52 Paclitaxel 48 Radiotherapy 47 Docetaxel 40 Gemcitabine 38 Cyclophosphamide 36 Rituximab 33 Capecitabine 28 Fluorouracil 27 Dexamethasone 27 Doxorubicin 26 Prednisone 21 Bevacizumab 20 Pemetrexed 19 Oxaliplatin 18 Leucovorin 18 Vincristine 17 Etoposide 17 pembrolizumab 16 Cytarabine 15 Drug Therapy 14 Irinotecan 13 Imatinib Mesylate 13 Filgrastim 13 Zoledronic Acid 12 Radiosurgery 12 Erlotinib Hydrochloride 12 Trastuzumab 11 Goserelin 11

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00607152 2014-05-08

Rasburicase (Fasturtec) Registration Trial

Sanofi

Phase 3 Terminated

Hyperuricemia

Data powered by HemOnc (CC BY 4.0) Colophon ⚡